143 related articles for article (PubMed ID: 36805562)
1. CRISPR/Cas9-mediated A4GALT suppression rescues Fabry disease phenotypes in a kidney organoid model.
Cui S; Shin YJ; Fang X; Lee H; Eum SH; Ko EJ; Lim SW; Shin E; Lee KI; Lee JY; Lee CB; Bae SK; Yang CW; Chung BH
Transl Res; 2023 Aug; 258():35-46. PubMed ID: 36805562
[TBL] [Abstract][Full Text] [Related]
2. Modeling of Fabry disease nephropathy using patient derived human induced pluripotent stem cells and kidney organoid system.
Cui S; Fang X; Lee H; Shin YJ; Koh ES; Chung S; Park HS; Lim SW; Lee KI; Lee JY; Yang CW; Chung BH
J Transl Med; 2023 Feb; 21(1):138. PubMed ID: 36814269
[TBL] [Abstract][Full Text] [Related]
3. Generation of a GLA knock-out human-induced pluripotent stem cell line, KSBCi002-A-1, using CRISPR/Cas9.
Kim YK; Yu JH; Min SH; Park SW
Stem Cell Res; 2020 Jan; 42():101676. PubMed ID: 31841972
[TBL] [Abstract][Full Text] [Related]
4. CRISPR-Cas9-Mediated Correction of
Lim SW; Fang X; Cui S; Lee H; Shin YJ; Ko EJ; Lee KI; Lee JY; Chung BH; Yang CW
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769335
[TBL] [Abstract][Full Text] [Related]
5. Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells.
Do HS; Park SW; Im I; Seo D; Yoo HW; Go H; Kim YH; Koh GY; Lee BH; Han YM
EBioMedicine; 2020 Feb; 52():102633. PubMed ID: 31981984
[TBL] [Abstract][Full Text] [Related]
6. Generation of a CRISPR/Cas9-corrected-hiPSC line (DDLABi001-A) from Fabry disease (FD)-derived iPSCs having α-galactosidase (GLA) gene mutation (c.803_806del).
Choi JB; Seo D; Do HS; Han YM
Stem Cell Res; 2023 Feb; 66():103001. PubMed ID: 36516658
[TBL] [Abstract][Full Text] [Related]
7. Human kidney organoids reveal the role of glutathione in Fabry disease.
Kim JW; Kim HW; Nam SA; Lee JY; Cho HJ; Kim TM; Kim YK
Exp Mol Med; 2021 Oct; 53(10):1580-1591. PubMed ID: 34654880
[TBL] [Abstract][Full Text] [Related]
8. Modeling of
Lim SW; Na D; Lee H; Fang X; Cui S; Shin YJ; Lee KI; Lee JY; Yang CW; Chung BH
Cells; 2023 Sep; 12(18):. PubMed ID: 37759541
[TBL] [Abstract][Full Text] [Related]
9. Medullary thick ascending limb impairment in the Gla
Maruyama H; Taguchi A; Nishikawa Y; Guili C; Mikame M; Nameta M; Yamaguchi Y; Ueno M; Imai N; Ito Y; Nakagawa T; Narita I; Ishii S
FASEB J; 2018 Aug; 32(8):4544-4559. PubMed ID: 29553830
[TBL] [Abstract][Full Text] [Related]
10. Using CRISPR/Cas9-Mediated GLA Gene Knockout as an In Vitro Drug Screening Model for Fabry Disease.
Song HY; Chiang HC; Tseng WL; Wu P; Chien CS; Leu HB; Yang YP; Wang ML; Jong YJ; Chen CH; Yu WC; Chiou SH
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27983599
[TBL] [Abstract][Full Text] [Related]
11. Dysregulation of Immune Response Mediators and Pain-Related Ion Channels Is Associated with Pain-like Behavior in the GLA KO Mouse Model of Fabry Disease.
Spitzel M; Wagner E; Breyer M; Henniger D; Bayin M; Hofmann L; Mauceri D; Sommer C; Üçeyler N
Cells; 2022 May; 11(11):. PubMed ID: 35681422
[TBL] [Abstract][Full Text] [Related]
12. Endothelial Cell Dysfunction and Hypoxia as Potential Mediators of Pain in Fabry Disease: A Human-Murine Translational Approach.
Klug K; Spitzel M; Hans C; Klein A; Schottmann NM; Erbacher C; Üçeyler N
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895103
[TBL] [Abstract][Full Text] [Related]
13. α-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease.
Bangari DS; Ashe KM; Desnick RJ; Maloney C; Lydon J; Piepenhagen P; Budman E; Leonard JP; Cheng SH; Marshall J; Thurberg BL
Am J Pathol; 2015 Mar; 185(3):651-65. PubMed ID: 25553976
[TBL] [Abstract][Full Text] [Related]
14. Characterization and phosphoproteomic analysis of a human immortalized podocyte model of Fabry disease generated using CRISPR/Cas9 technology.
Pereira EM; Labilloy A; Eshbach ML; Roy A; Subramanya AR; Monte S; Labilloy G; Weisz OA
Am J Physiol Renal Physiol; 2016 Nov; 311(5):F1015-F1024. PubMed ID: 27681560
[TBL] [Abstract][Full Text] [Related]
15. Proteomic analysis unveils Gb3-independent alterations and mitochondrial dysfunction in a gla
Elsaid HOA; Rivedal M; Skandalou E; Svarstad E; Tøndel C; Birkeland E; Eikrem Ø; Babickova J; Marti HP; Furriol J
J Transl Med; 2023 Sep; 21(1):591. PubMed ID: 37670295
[TBL] [Abstract][Full Text] [Related]
16. Gene-Edited Fluorescent and Mixed Cerebral Organoids.
Bachmann L; Gallego Villarejo L; Heinen N; Marks D; Peters M; Müller T
CRISPR J; 2022 Feb; 5(1):53-65. PubMed ID: 35099270
[TBL] [Abstract][Full Text] [Related]
17. Generation of human induced pluripotent stem cell line MHHi029-A from a male Fabry disease patient carrying c.959A > T mutation.
Jahn C; Juchem M; Sonnenschein K; Gietz A; Buchegger T; Lachmann N; Göhring G; Behrens YL; Bär C; Thum T; Hoepfner J
Stem Cell Res; 2024 Jun; 77():103404. PubMed ID: 38552356
[TBL] [Abstract][Full Text] [Related]
18. Reversal of the Inflammatory Responses in Fabry Patient iPSC-Derived Cardiovascular Endothelial Cells by CRISPR/Cas9-Corrected Mutation.
Song HY; Yang YP; Chien Y; Lai WY; Lin YY; Chou SJ; Wang ML; Wang CY; Leu HB; Yu WC; Chien CS
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673551
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic correction of hemophilia A using 2D endothelial cells and multicellular 3D organoids derived from CRISPR/Cas9-engineered patient iPSCs.
Son JS; Park CY; Lee G; Park JY; Kim HJ; Kim G; Chi KY; Woo DH; Han C; Kim SK; Park HJ; Kim DW; Kim JH
Biomaterials; 2022 Apr; 283():121429. PubMed ID: 35217482
[TBL] [Abstract][Full Text] [Related]
20. Human-induced pluripotent stem cell lines (CMCi006-A and CMCi007-A) from a female and male patient with Fabry disease carrying the same frameshift deletion mutation.
Cui S; Shin YJ; Ko EJ; Lim SW; Ju JH; Lee KI; Lee JY; Yang CW; Chung BH
Stem Cell Res; 2021 Mar; 51():102214. PubMed ID: 33545641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
